ORIGINAL REPORT



COGNITIVE AND EMOTIONAL SYMPTOMS IN PATIENTS WITH FIRST-EVER MILD STROKE: THE SYNDROME OF HIDDEN IMPAIRMENTS

Georgios VLACHOS, MD^{1,2}, Hege IHLE-HANSEN, MD, PhD^{1,3}, Torgeir BRUUN WYLLER, MD, PhD^{1,2}, Anne BRÆKHUS, MD, PhD^{1,4}, Margrete MANGSET, RN, PhD¹, Charlotta HAMRE, PT, MSc^{1,5} and Brynjar FURE, MD, PhD⁶⁻⁸ From the ¹Department of Geriatric Medicine, Oslo University Hospital, ²Institute of Clinical Medicine, University of Oslo, Oslo, ³Department of Internal Medicine, Bærum Hospital, Vestre Viken, ¹Department of Neurology, Oslo University Hospital, ⁵Department of Physiotherapy, Oslo University Hospital, Oslo, Norway, ⁵Department of Internal Medicine, Central Hospital, ¬Department of Neurology, Central Hospital, Karlstad, and °School of Medical Sciences, Örebro University, Örebro, Sweden

Objective: To evaluate the prevalence of cognitive and emotional impairments one year after first-ever mild stroke in younger patients.

Design: Prospective, observational, cohort study.

Subjects: A consecutive sample of 117 previously cognitively healthy patients aged 18-70 years with mild stroke (National Institutes of Health Stroke Scale score ≤3) were included in 2 hospitals in Norway during a 2-year period.

Methods: At 12-month follow-up, patients were assessed using validated instruments for essential cognitive domains, fatigue, depression, anxiety, apathy and pathological laughter and crying.

Results: In total, 78 patients (67%) had difficulty with one or a combination of the cognitive domains psychomotor speed, attention, executive and visuospatial function, and memory. Furthermore, 50 patients (43%) had impairment in either one or a combination of the emotional measures for anxiety, depressive symptoms, fatigue, apathy or emotional lability. A total of 32 patients (28%) had both cognitive and emotional impairments. Only 21 patients (18%) scored within the reference range in all the cognitive and emotional tools.

Conclusion: Hidden impairments are common after first-ever mild stroke in younger patients. Stroke physicians should screen for hidden impairments using appropriate tools.

Key words: mild stroke; younger patients; cognitive impairment; depression; anxiety; apathy; fatigue; hidden impairments

Accepted Oct 13, 2020; Epub ahead of print Nov 4, 2020

J Rehabil Med 2021; 53: jrm00135

Correspondence address: Georgios Vlachos, Georgios Vlachos, MD, Stroke Unit, Department of Neurology, Oslo University Hospital, Postbox 4956 Nydalen, 0424 Oslo, Norway. E-mail: georgios.vlachos@ous-hf.no

Outcome after stroke has improved remarkably over recent years due to better prevention and improved acute treatments in the stroke units (1) and by reperfusion therapy (2).

Still, independently of age and lesion size, cognitive and emotional impairments after stroke are common, with a prevalence of dementia of up to 20% and of mild cognitive impairment (MCI) of 38% in a general stroke sample one year after onset of symptoms (3), and a

LAY ABSTRACT

Many patients with minimal or no apparent neurological deficits after stroke may experience cognitive and emotional symptoms. The quality of life and functioning of these patients may be reduced. Our research group studied 117 previously cognitively healthy patients aged 70 years or younger with mild stroke 12 months after the stroke event. They were assessed for cognitive and emotional impairments using validated tests for cognitive function, fatigue, depression, anxiety, and apathy. Only 21 patients (18%) scored within the normal range in these tests. In conclusion, "hidden impairments" are common among younger stroke patients. It is important for patients, their surroundings and stroke physicians to be aware that such difficulties can occur after even a mild stroke.

prevalence of depression and anxiety reaching 30% and 20–25%, respectively (4). However, the number of cognitive and emotional impairments detected after stroke vary due to heterogeneity in the cognitive instruments, used diagnostic criteria and demographic factors, such as educational level, vascular risk factors and comorbidity. Since even first-ever stroke can lead to cognitive deficits in patients who are previously cognitively intact, it has been suggested that future research on post-stroke cognitive deficits should focus on this patient group (5).

Persons with minimal neurological deficits after stroke are often discharged shortly after admittance, with the observation that "everything seems to be alright". However, on return to their everyday lives, they may realize that their quality of life and functioning has changed. These patients may face difficulties affecting their memory, concentration, attention, and commonly experience fatigue (6). Pendlebury et al. (7) showed that, in a sample of patient with minor stroke, 8.2% were diagnosed with dementia one year after stroke, which was significantly higher than for an age-matched general population. Emotional impairments, such as anxiety, depression and apathy, can also occur (6, 8). It has been suggested that younger persons are at particular risk of developing disabling cognitive and emotional impairments after stroke (9).

As a consequence, patients with stroke, stroke patients' organizations, and health professionals have introduced the concept of "hidden impairments" (10). The syndrome of hidden impairments is proposed to include cognitive and emotional impairments that

doi: 10.2340/16501977-2764

are not revealed through neurological examination or cognitive and emotional screening instruments used in clinical daily routine (10). Hidden impairments may include executive dysfunction, memory impairment, language difficulties, reduced psychomotor speed, fatigue, pathological laughter and crying, anxiety, depression, and apathy. The aim of this prospective, observational, cohort study was to evaluate the prevalence of hidden impairments 12 months after first-ever mild stroke in patients aged 70 years or younger.

MATERIAL AND METHODS

Population

From December 2014 until December 2016, patients with first-ever ischaemic or haemorrhagic stroke admitted to the acute stroke units of Oslo University Hospital and Bærum Hospital were consecutively included in the study. Inclusion criteria were: patients aged 18–70 years, who had had mild strokes, defined as a National Institutes of Health Stroke Scale (NIHSS) (11) score \leq 3 at discharge (12).

Patients with pre-stroke cognitive decline as indicated by a score > 3.2 on the short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) (13), patients who did not speak Norwegian, and patients with known psychiatric disease were not eligible for inclusion. Patients who experienced a new stroke during the first year after discharge from the stroke unit were not invited to follow-up.

Diagnostic evaluation

The diagnosis of stroke was based on the history of symptoms, the findings on the neurological examination, and the findings of an acute infarction or haemorrhage on cerebral computed tomography (CT) or magnetic resonance imaging (MRI) scans. Patients with no acute haemorrhagic or ischaemic lesions on CT or MRI, but with neurological deficits compatible with ce-

rebrovascular disease lasting more than 24 h, were considered to have an ischaemic stroke (14).

Ischaemic strokes were classified according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) (15), and the Oxfordshire Community Stroke Project (OCSP) classifications (16).

Assessments

Vascular risk factors, including hypertension, hyperlipidaemia, coronary heart disease, atrial fibrillation, cigarette smoking and diabetes mellitus, were recorded, and body mass index (BMI) calculated. A diagnosis of atrial fibrillation required electrocardiogram (ECG) confirmation pre-stroke or during the hospital stay.

Neurological impairments were assessed with the NIHSS (11) at admission and discharge by a stroke physician or a stroke nurse. Patients were screened for pre-stroke cognitive impairment with the 16-question version of the IQCODE (13), which was completed by first-degree relatives or another next-of-kin. Due to the younger age and high educational level of included patients, a cut-off of 3.2 was used to minimize the probability of including patients with a pre-stroke cognitive impairment. Patients who had previously been diagnosed with dementia or mild cognitive impairment were not included.

Activities of daily living (ADL) were assessed with the Barthel ADL index (17) and general functional level with the modified Rankin Scale score (mRS) (17) at discharge and at 12-month follow-up.

All participants were invited to a 12-month follow-up at the Stroke Outpatient Clinic. The duration of the sessions was at most 2 h. Pauses during the tests were allowed if needed. The cognitive and emotional assessments were performed by either stroke physicians (authors GV and HI-H), occupational therapists, or by a nurse in the stroke units and the stroke outpatient clinics. The professionals carrying out the tests had been trained by physicians with wide experience in that field. The choice of the cut-offs was discussed with neuropsychologists.

Cognitive and emotional assessment

At the 12-month follow-up cognitive and emotional domains were evaluated using the tests shown in Table I.

Table I. Used tests, domains tested, and cut-off values at the 12-month follow-up

Screening instrument	Domain	Cut-off
MMSE-NR2	Global cognitive functioning	< 27/30 (19)
Clock Drawing test	Executive functioning, visuospatial functioning	<4/5 (20)
Trail Making Test A	Focused attention, psychomotor speed	>60 s (21)
Trail Making Test B	Divided attention, executive functioning, psychomotor speed	>120 s (21)
COWA, Verbal Fluency test (FAS)	Attention, executive functioning, psychomotor speed, language ability	≤ Normative sample mean −1 SD (22)
Rey-Osterrieth Complex Figure, copy	Executive functioning, visuospatial functioning, memory	≤ Normative sample mean −1 SD (23) ≤ Normative sample
Rey-Osterrieth Complex Figure, delayed recall		mean -1 SD (23)
CVLT II, total learning	Learning ability	≤ Normative sample mean -1 SD (24)
CVLT II, short delay free recall	Memory	≤Normative sample mean -1 SD (24)
CVLT II, long delay, free recall		≤ Normative sample mean −1 SD (24)
Hospital Anxiety and Depression Scale	Anxiety Depression	>7 points for anxiety (26) >7 points for depression (26)
Fatigue Severity Scale	Fatigue	≥ 4 points (27)
Apathy Evaluation Scale-Self Report	Apathy	≥34 points (28)
Pathological Laughter And Crying Scale	Emotional instability	≥13 points (29)

 $MMSE-NR2: Norwegian \ Revised \ version\ 2\ of \ the\ Mini-Mental\ State\ Examination;\ COWA:\ Controlled\ Oral\ Word\ Association;\ CVLT\ II:\ California\ Verbal\ Learning\ Test-II.$

The Mini Mental State Examination Norwegian Revision 2 (MMSE NR2) (18) is a global screening test of cognitive functioning. Optimal cut-off values vary with age and educational level. A relatively high score (<27 points) was chosen as a cut-off, since most patients were younger than 70 years and well educated (19).

The Clock Drawing test (20) is sensitive for visuospatial and executive functions. Patients who scored <4/5 points in the Clock Drawing test were considered cognitively impaired.

The Trail Making Tests (TMT) A and B (21) were used to assess psychomotor speed and focused or divided attention. In addition, TMT B is sensitive for executive functioning. A cut-off between normal and pathological functioning was chosen as correct administration of the TMT A within 60 s, and the TMT B within 120 s. The TMT B was interrupted after 5 min (300 s) if the participant was not able to complete it during that time.

The Controlled Oral Word Association (COWA) Verbal Fluency test (22) evaluates language ability, psychomotor speed, attention and executive functioning. Patients name as many words beginning with letters F, A, S as possible within one min for each letter.

The Rey-Osterrieth Complex Figure Test (ROCF) (23) requires subjects to copy a complex figure, and then reproduce it after 20 min. This tests memory as well as visuospatial and executive functions.

For assessment of learning ability and memory, the California Verbal Learning Test II (CVLT II) (24) was used where patients try to learn a 16-word list, and to recall it after 20 min.

Due to the evidence for age-related and, in some tests, sexrelated differences on cognitive test scores, raw scores were converted into standardized scores (mean 50; standard deviation (SD) 10) separately for each sex and age category for CVLT II, for age for ROCF, and for age and education level for COWA and the Trail Making tests. Impairment of each cognitive domain was defined as a score of at least 1 SD below appropriate normative sample according to the test manuals used at The Memory Clinic of the Department of Geriatric Medicine at Oslo University Hospital. According to the International Society for Vascular Behavioral and Cognitive Disorders (VASCOG) criteria (25) for the diagnosis of cognitive impairment, mild cognitive disorder can be present when the performance on objective validated cognitive tools in one or more cognitive domains (attention, processing speed, executive function, learning and memory, language, visuocontructional-perceptual ability, praxis-gnosis-body schema, social cognition) is in the range 1-2 SD below appropriate norms. A cut-off of -1 SD below appropriate norms was chosen due to the patients' younger age $(\leq 70 \text{ years})$ and high educational level.

The presence of anxiety and depression symptoms was evaluated with the 14-item Hospital Anxiety and Depression Scale (HADS) (26). The cut-off was > 7 points for each of the 2 domains depression and anxiety.

Post-stroke fatigue (PSF) was defined as the well-established cut-off of ≥ 4 points on the 9-item Fatigue Severity Scale (FSS) (27), which is a widely used instrument in stroke studies.

The 18-item Apathy Evaluation Scale-Self report (AES-S) (28) was used to assess the presence and severity of post-stroke apathy (PSA). Patients with a score ≥34 points were classified as having clinically relevant apathy.

The Pathological Laughter and Crying Scale (PLACS) (29) was used to assess the presence of emotional lability, characterized as uncontrolled laughter or crying in appropriate situations. The cut-off was \geq 13 points.

Cognitive impairment was considered to be present whenever a patient had a score outside the reference range on at least one of the cognitive tests, and an emotional impairment whenever a patient scored outside the reference range on at least one emotional instrument.

Statistical analysis

Statistical analyses were performed with the Statistical Package for Social Sciences (SPSS), version 25.0, using descriptive statistics. Data are presented with means and SD for continuous variables, and with proportions and percentages for categorical variables. The rating scale scores are represented with median, where the data distribution was skewed, and range.

Ethics

The study was approved by the Regional Committee for Ethics in Medical Research (register number 2014/1268), and by the Hospital's Data Protection Authority. All patients gave their written informed consent before inclusion.

RESULTS

In total, 127 patients with first-ever ischaemic or haemorrhagic stroke admitted to the acute stroke units of Oslo University Hospital (99 patients) or Bærum Hospital (28 patients), were included. Mean age was 55.7 years (SD 11.3; range 30–70 years), and 98 (77%) were male. Of the included patients, 119 (94%) had an ischaemic and 8 (6%) had a haemorrhagic stroke. Mean education length was 15.3 years (SD 3.6 years). One included patient had expressive aphasia at discharge diagnosed by a speech therapist.

The clinical characteristics of all patients at admission are shown in Table II.

12-month follow-up: cognitive and emotional assessments

At the 12-month follow-up, 117 patients (92%) were available. During the first post-stroke year, 4 patients had a new stroke and were not invited to the follow-up, one patient died from cardiac disease and 5 patients did not wish to complete the follow-up period.

Table III shows the results of the cognitive and the emotional instruments used at 12-month follow-up.

Cognitive assessments

On the MMSE, the Clock Drawing test and the TMT A, most patients scored within the normal range, whereas on the TMT B, 11% of male and 8% of female patients had a score > 120 s. Applying a strict cut-off of ≤ -1 SD below the appropriate norms, 43% of male and 30% of female patients had a score below cut-off on the COWA Verbal Fluency test. For the ROCF delayed recall, 31% of male and 22% of female patients scored below a cut-off of ≤ -1 SD.

In total, only 33% of the patients scored within the reference range on all tests; the remaining patients had

Table II. Baseline characteristics of all patients

Baseline characteristics	Table II. Baseline characteristics of all patients				
Variables Demographics Age, years, mean (SD) [range] 55.7 (11.3) 56.5 (10.7) 53.4 (12.9) [30-70] [30-70] [31-70] [30-69] Age group 18-39 years, n (%) 13 (10) 10 (10) 3 (10) 3 (10) Age group 40-59 years, n (%) 55 (43) 42 (43) 13 (45) Age group 60-70 years, n (%) 59 (47) 46 (47) 13 (45) Education, years, mean (SD) 15.3 (3.6) 15.5 (3.5) 14.5 (3.9) Risk factors, n (%) Hypertension 59 (47) 50 (51) 9 (31) Hypertipidaemia (total cholesterol > 5 90 (71) 76 (78) 14 (48) Or LDL > 3 mmol/I) Coronary disease (myocardial 14 (11) 14 (14) 0 (0) Infarction, angina pectoris) Atrial fibrillation 11 (9) 10 (10) 1 (3) 1 (3) Cigarette smoking (≥1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes mellitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Stroke of undetermined aetiology 31	Raceline characteristics	sample,			
Demographics Age, years, mean (SD) [range] 55.7 (11.3) 56.5 (10.7) 53.4 (12.9) [30-70] [31-70] [30-69] [30-70] [31-70] [30-69] [30-70] [31-70] [30-69] [30-70] [30-70] [30-69] [30-70] [30-70] [30-69] [30-70]			11 – 30	11-23	
Age, years, mean (SD) [range] 55.7 (11.3) 56.5 (10.7) [30-69] [
Age group 18–39 years, n (%) 13 (10) 10 (10) 3 (10) Age group 40–59 years, n (%) 55 (43) 42 (43) 13 (45) Age group 60–70 years, n (%) 59 (47) 46 (47) 13 (45) Education, years, mean (SD) 15.3 (3.6) 15.5 (3.5) 14.5 (3.9) Risk factors, n (%) Hypertension 59 (47) 50 (51) 9 (31) Hypertension Hyperlipidaemia (total cholesterol > 5 90 (71) 76 (78) 14 (48) or LDL > 3 mmol/l) Coronary disease (myocardial infarction, angina pectoris) Atrial fibrillation 11 (9) 10 (10) 1 (3) Cigarette smoking (≥ 1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes mellitus 15 (12) 14 (14) 1 (3) Stroke subtype, n (%) Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic Ramorrians (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 20 (17) 16 (18) 4 (15) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) CSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (PACI) 33 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Assessments NIHSS day 1, median (range) 1 (0–4) 1 (0–4) MRS O+1 at discharge, median (range) 1 (0–4) 1 (0–4) MRS O+1 at discharge, median (range) 1 (0–4) 1 (0–4) MRS O+1 at discharge, median (range) 1 (10–20) 1 (17–20) (13–20) Cognitive assessments 10 COODE, mean (SD) 3.02 3.03 3.01					
Age group 18–39 years, n (%) 13 (10) 10 (10) 3 (10) Age group 40–59 years, n (%) 55 (43) 42 (43) 13 (45) Age group 60–70 years, n (%) 59 (47) 46 (47) 13 (45) Education, years, mean (SD) 15.3 (3.6) 15.5 (3.5) 14.5 (3.9) Risk factors, n (%) 19 (47) 50 (51) 9 (31) Hypertension 59 (47) 50 (51) 9 (31) Hypertingidemia (total cholesterol > 5 or LDL > 3 mmol/l) 14 (11) 14 (14) 0 (0) Coronary disease (myocardial infarction, angina pectoris) 11 (9) 10 (10) 1 (3) Atrial fibrillation 11 (9) 10 (10) 1 (3) Cigarette smoking (≥1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes mellitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) 119 (94) 92 (94) 27 (93) Iscaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) 16 (18)<	Age, years, mean (SD) [range]				
Age group 40–59 years, n (%) Age group 60–70 years, n (%) Age group 60–70 years, n (%) Education, years, mean (SD) Hypertension Fish factors, n (%) Hypertension Fighther factors, n (%)	Age group 18–39 years in (%)				
Age group 60–70 years, n (%) 59 (47) 46 (47) 13 (45) Education, years, mean (SD) 15.3 (3.6) 15.5 (3.5) 14.5 (3.9) Risk factors, n (%) Hypertension 59 (47) 50 (51) 9 (31) Hypertension 10 10 (76 (78) 14 (48) or LDL > 3 mmol/I) Coronary disease (myocardial infarction, angina pectoris) Atrial fibrillation 11 (9) 10 (10) 1 (3) Cigarette smoking (≥1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes mellitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 27.4 (4.1) Stroke subtype, n (%) Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of undetermined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 37 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-22) 1 (0-22) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-7) 1 (10 (11-20) mRS 0-1 at discharge, median (range) 1 (0-7) 1 (10 (11-20) mRS 0-1 at discharge, median (range) 1 (0-7) 1 (0-7) 1 (0-7) 1 (0-7)	, , , , ,	. ,	. ,	. ,	
Education, years, mean (SD) Risk factors, n (%) Hypertension Hyperlipidaemia (total cholesterol > 5 9 (7) 76 (78) Hyperlipidaemia (total cholesterol > 5 90 (7) 76 (78) Hyperlipidaemia (total cholesterol > 5 90 (7) 76 (78) Hyperlipidaemia (total cholesterol > 5 90 (7) 76 (78) Hyperlipidaemia (total cholesterol > 5 90 (71) 76 (78) Hyperlipidaemia (total cholesterol > 5 90 (71) 76 (78) Hyperlipidaemia (total cholesterol > 5 90 (71) 76 (78) Hyperlipidaemia (total cholesterol > 5 90 (71) 76 (78) Hyperlipidaemia (total cholesterol > 5 90 (71) 76 (78) Hyperlipidaemia (total cholesterol > 11 (9) 10 (10) 1 (3) Cigarette smoking (≥1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes mellitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 32 (27) 26 (28) 6 (22) Small vessel disease 32 (27) 26 (28) 6 (22) Stroke of other determined aetiology 3 (2) 1 (1) 2 (7) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 37 (7) 1 (3) Assessments NIHSS at discharge, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-7) 1 (10 (1) 19.7 (1.3) [range] (00) 11 (10) 10 (10) 10 (10) 10 (10) 10 (10) 10 (10)	, , , , ,	. ,	. ,	. ,	
Risk factors, n (%) Hypertension 59 (47) 50 (51) 9 (31) Hypertension 59 (071) 76 (78) 14 (48) or LDL > 3 mmol/I) Coronary disease (myocardial infarction, angina pectoris) Atrial fibrillation 11 (9) 10 (10) 1 (3) Cigarette smoking (\geq 1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes mellitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 37 (7) 1 (3) Assessments NIHSS at discharge, median (range) 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS at discharge, median (range) 1 (0-22) 1 (0-22) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-7) 1 (17) 10 (17	, , , , ,	. ,	. ,	. ,	
Hypertension 59 (47) 50 (51) 9 (31) Hyperlipidaemia (total cholesterol > 5 90 (71) 76 (78) 14 (48) or LDL > 3 mmol/l) Coronary disease (myocardial infarction, angina pectoris) Atrial fibrillation 11 (9) 10 (10) 1 (3) Cigarette smoking (≥1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes mellitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 47 (37) 38 (37) 38 (37) Left hemisphere 47 (37) 38 (37) 38 (37) Left hemisphere 48 (36) 37 (37) 38 (37) Left hemisphere 47 (37) 38 (37) 38 (37) Left hemisphere 48 (36) 38 (39)		13.3 (3.0)	13.3 (3.3)	11.5 (5.5)	
Hyperlipidaemia (total cholesterol > 5 90 (71) 76 (78) 14 (48) or LDL > 3 mmol/l) Coronary disease (myocardial infarction, angina pectoris) Atrial fibrillation 11 (9) 10 (10) 1 (3) Cigarette smoking (≥1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes mellitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) NIHSS at discharge, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-7) 1 (10) 10 (11) 10 (10		59 (47)	50 (51)	9 (31)	
or LDL > 3 mmol/l) Coronary disease (myocardial infarction, angina pectoris) Atrial fibrillation 11 (9) 10 (10) 1 (3) Cigarette smoking (≥ 1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes mellitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 32 (27) 26 (28) 6 (22) Small vessel disease 32 (27) 26 (28) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) Sessements NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19,7 (1.1) 19,7 (1.1) 19,7 (1.3) [range] [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01		. ,	. ,	. ,	
infarction, angina pectoris) Atrial fibrillation 11 (9) 10 (10) 1 (3) Cigarette smoking (≥1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes mellitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Stroke of undetermined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) <td></td> <td>,</td> <td>- (-)</td> <td>(-)</td>		,	- (-)	(-)	
Atrial fibrillation (≥1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes melitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 46 (36) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01	Coronary disease (myocardial	14 (11)	14 (14)	0 (0)	
Cigarette smoking (≥1 cigarette/day) 33 (26) 27 (27) 6 (20) Diabetes mellitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 32 (27) 26 (28) 6 (22) Small vessel disease 32 (27) 26 (28) 6 (22) Small vessel disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21	,				
Diabetes mellitus 15 (12) 14 (14) 1 (3) BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) 8 (38) 8 (38) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41)		, ,	, ,	, ,	
BMI, mean (SD) 26.9 (4.4) 27.4 (4.4) 25.4 (4.1) Stroke subtype, n (%) 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) User (4.1) 4 (15) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 3 (2) 1 (1) 2 (7) Stroke of undetermined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (PACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) 8 (8) 38 (39) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) Left		. ,			
Stroke subtype, n (%) Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) 10 (34) OCSP classification infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) 8 (8) 8 (39) 8 (28) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere		. ,	. ,		
Ischaemic 119 (94) 92 (94) 27 (93) Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) 8 (38) 8 (38) 8 (28) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) <t< td=""><td></td><td>26.9 (4.4)</td><td>27.4 (4.4)</td><td>25.4 (4.1)</td></t<>		26.9 (4.4)	27.4 (4.4)	25.4 (4.1)	
Haemorrhagic 8 (6) 6 (6) 2 (7) TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 3 (2) 1 (1) 2 (7) Stroke of undetermined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) 10 (34) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) 8 (38) 8 (38) 8 (38) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) <	** * * *				
TOAST classification (ischaemic strokes), n (%) Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01			. ,		
Large vessel disease 20 (17) 16 (18) 4 (15) Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (2) 1 (1) 2 (7) Stroke of undetermined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (PACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) 8 (38) 8 (38) 8 (28) Left hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3)	_		6 (6)	2 (7)	
Cardio embolic disease 32 (27) 26 (28) 6 (22) Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) 8 (38) 8 (39) 8 (28) Right hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) <	•	. ,	15 (10)	4 (4 =)	
Small vessel disease 33 (28) 28 (30) 5 (19) Stroke of other determined aetiology 3 (2) 1 (1) 2 (7) Stroke of undetermined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) 70 10 (34) OCSP classification at admission (ischaemic strokes), n (%) 3 (3) 1 (4) Partial anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Post	3	, ,		` ,	
Stroke of other determined aetiology 3 (2) 1 (1) 2 (7) Stroke of undetermined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) 10 (34) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) 8 (8) 8 (39) 8 (28) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22)		, ,	, ,	. ,	
Stroke of undetermined aetiology 31 (26) 21 (23) 10 (34) OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) 8 (38) 8 (39) 8 (28) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) MRS at discharge, median (range)<			, ,	. ,	
OCSP classification at admission (ischaemic strokes), n (%) Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) 70 8 (38) 8 (28) 8 (28) 8 (28) 12 (41) 6 (21) Right hemisphere 46 (36) 38 (39) 8 (28) 12 (41) 6 (21) 6 (22) 12 (41) 6 (21) 12 (41) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (14) 6 (21) 14 (15) 14 (15) 14 (14) 6 (21) <td></td> <td>` ,</td> <td>` ,</td> <td>` ,</td>		` ,	` ,	` ,	
Total anterior circulation infarct (TACI) 4 (3) 3 (3) 1 (4) Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) 8 (28) 29 (32) 6 (22) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) MRS ot discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) MRS 0-1 at discharge, median (range) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] <td>3,</td> <td>. ,</td> <td>. ,</td> <td>10 (34)</td>	3,	. ,	. ,	10 (34)	
Partial anterior circulation infarct (PACI) 53 (45) 39 (42) 14 (52) Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] [11-20] [11-20] [13-20] Cognitive assessments IQCODE, mean (SD)	,		. ,	1 (4)	
Lacunar infarct (LACI) 27 (23) 21 (23) 6 (22) Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01	` ,		. ,		
Posterior circulation infarct (POCI) 35 (29) 29 (32) 6 (22) Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, median (range) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 13.20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01	` ,	, ,	. ,	. ,	
Topography, MR/CT-findings, n (%) Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01	` ,	. ,	. ,	. ,	
Right hemisphere 46 (36) 38 (39) 8 (28) Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 19.7 (1.1) 10.20 [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01		33 (29)	29 (32)	0 (22)	
Left hemisphere 36 (28) 24 (25) 12 (41) Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] [11-20] [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01		46 (36)	38 (30)	8 (28)	
Cerebellum/brainstem 20 (16) 14 (14) 6 (21) Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] [11-20] [11-20] [13-20] Cognitive assessments 3.02 3.03 3.01		. ,	. ,	. ,	
Multiple brain regions 17 (13) 15 (15) 2 (7) No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] [11-20] [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01	•	. ,	. ,	. ,	
No acute lesions on CT or MRI 8 (6) 7 (7) 1 (3) Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] [11-20] [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01		. ,	. ,	. ,	
Assessments NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] [11-20] [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01		. ,	. ,		
NIHSS day 1, median (range) 1 (0-22) 1 (0-22) 1 (0-8) NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] [11-20] [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01		0 (0)	, (,)	1 (3)	
NIHSS at discharge, median (range) 0 (0-3) 0 (0-3) 0 (0-3) mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] [11-20] [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01		1 (0-22)	1 (0-22)	1 (0-8)	
mRS at discharge, median (range) 1 (0-4) 1 (0-4) 1 (0-4) mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) [19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] [11-20] [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01	,			. ,	
mRS 0-1 at discharge, n (%) 98 (77) 76 (78) 22 (76) Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] [11-20] [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01	- ' ' - '	, ,			
Barthel Index at discharge, mean (SD) 19.7 (1.1) 19.7 (1.1) 19.7 (1.3) [range] [11-20] [11-20] [13-20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01		, ,		. ,	
[range] [11–20] [11–20] [13–20] Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01	,	. ,	. ,	. ,	
Cognitive assessments IQCODE, mean (SD) 3.02 3.03 3.01					
	Cognitive assessments				
(0.07) (0.08) (0.03)	IQCODE, mean (SD)				
		(0.07)	(0.08)	(0.03)	

BMI: body mass index; TOAST: Trial of Org 10172 in Acute Stroke Treatment; OCSP: Oxfordshire Community Stroke Project Classification; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly. SD: standard deviation

scores outside the reference range on 1–8 tests (see Fig. 1). This means that, according to the VASCOG criteria (25), 67% of patients 70 years and younger at stroke onset, might have a cognitive impairment 12 months after first-ever mild stroke.

Emotional assessments

A total of 18 patients (15%) had a high score on the anxiety scale, and 15 patients (13%) on the depression scale. A total of 15 patients (13%) had an elevated score for the combined anxiety-depression scale. The prevalence of anxiety was 30% for women and 11% for men, while 22% of women and 10% of men had symp-

Table III. Cognitive and emotional functioning 12 months after stroke.

	Total sample,	Male,	Female,	
12-month follow-up	n = 117	n = 90	n = 27	
Variables				
Assessments				
mRS, median (range)	1 (0-3)	1 (0-3)	1 (0-3)	
mRS 0-1, n (%)	88 (75)	72 (80)	16 (59)	
mRS 2, n (%)	26 (22)	17 (19)	9 (33)	
mRS 3, n (%)	3 (3)	1(1)	2 (8)	
Barthel Index, mean (SD) [range]	19.9 (0.1) [19-20]	20.0 (0.0) [20-20]	19.9 (0.2) [19-20]	
Cognitive assessments, n (%)				
MMSE-NR2 score < 27/30	4 (3)	2 (2)	2 (8)	
Clock drawing score < 4/5	5 (4)	3 (3)	2 (8)	
TMT A, time > 60 s	1 (1)	0 (0)	1 (4)	
TMT B, time > 120 s	12 (10)	10 (11)	2 (8)	
COWA, Verbal Fluency ≤-1 SD	46 (40)	38 (43)	8 (30)	
ROCF, copy ≤-1 SD	11 (9)	9 (10)	2 (8)	
ROCF, delayed recall ≤-1 SD	34 (29)	28 (31)	6 (22)	
CVLT-II, total learning ≤-1 SD	6 (5)	3 (3)	3 (11)	
CVLT-II, short delay free recall ≤-1SD	15 (13)	10 (11)	5 (18)	
CVLT-II, long delay free recall ≤-1SD	9 (8)	5 (5)	4 (15)	
Emotional assessments, n (%)				
HADS-Anxiety Scale, > 7 points	18 (15)	10 (11)	8 (30)	
HADS-Depression Scale, > 7 points	15 (13)	9 (10)	6 (22)	
HADS-Total, > 14 points	15 (13)	7 (8)	8 (30)	
FSS, ≥4 points	38 (33)	23 (26)	15 (56)	
AES-S, ≥34 points	29 (25)	21 (23)	8 (30)	
PLACS, ≥13 points	4 (3)	1 (1)	3 (11)	

mRS: modified Rankin Scale; MMSE-NR2: Norwegian Revised version 2 of the Mini-Mental State Examination; TMT A: Trail Making Test A; TMT B: Trail Making Test B; COWA: Controlled Oral Word Association; ROCF: Rey-Osterrieth Complex Figure; CVLT II: California Verbal Learning Test-II; HADS: Hospital Anxiety and Depression Scale; FSS: Fatigue Severity Scale; AES-S: Apathy Evaluation Scale-Self Report; PLACS: Pathological Laughter And Crying Scale. SD: standard deviation.

toms of depression. Analyses of FSS showed that 38 patients (33%) reported elevated scores. The prevalence among women was 56%, while it was 26% among men. Furthermore, 29 patients (25%) had a score \geq 34 points on AES-S. Concerning pathological laughter and crying tested by the PLACS, the prevalence of a score above cut-off for women was 11%, while it was low for men (1%) as well as for the whole sample (3%).

In total, 43% had a score outside the reference range on at least one emotional instrument (see Fig. 2).

As illustrated in Fig. 3, 18% of the total sample had neither cognitive nor emotional deficits that were




Fig. 1. Distribution of patients with cognitive test results outside reference range 12 months after stroke.





Fig. 2. Distribution of patients with emotional test results outside reference range 12 months after stroke.



- A: Cognitive impairments
- B: Emotional impairments
- C: Free from cognitive and emotional impairments

Fig. 3. Frequency of cognitive and emotional impairments 12 months after stroke.

detectable with the instruments used at one year after stroke. At 12-month follow-up 39% of the sample had only cognitive deficits, 15% had only emotional deficits, while 28% had both cognitive and emotional deficits.

DISCUSSION

This study indicates that one year after stroke, approximately 2 out of 3 patients aged 30–70 years, and with mild neurological symptoms may have difficulties with cognitive functions, such as psychomotor speed, attention, executive function, visuospatial function or memory, either alone or in combination with each other. Nearly every second patient may have impairment in either one or a combination of the emotional domains anxiety, depressive symptoms, fatigue, apathy, or emotional lability. Only one out of 5 could be considered as not having any cognitive or emotional impairments that were detectable with our instruments 12 months after stroke. This is in line with our clinical experience from the stroke outpatient clinic, based on the cognitive and emotional symptoms patients report at routine follow-up during the first year after stroke.

As also reported by others (10), this study found that the MMSE was insensitive to detect impairment of global cognitive functioning in patients with mild neurological impairments, despite the fact that a high cut-off (<27/30) was used. We assume that this result is related to the younger age and high educational level of our patients (19). In addition, the MMSE does not capture executive functioning or psychomotor speed at all (30). More sensitive tests, such as the Clock Drawing Test, the TMT A and B, the ROCF, the Verbal Fluency test and the CVLT II, are necessary in order to evaluate cognitive domains, such as executive and visuospatial functioning, psychomotor speed, attention, memory, and learning and language ability. The test results indicate that psychomotor speed, attention, executive functioning, visuospatial function, language ability, and memory were affected in both sexes, while the prevalence of impaired learning ability was higher in women. There were more men who took over 120 s to administer the TMT B. Just one patient took over 60 s to administer the TMT A. We believe that this was due to the young age and high educational level of the included patients. MMSE was used as this was the standard cognitive tool at the 2 study sites during the study period. However, due to its wider spectre of covered domains we now recommend the Montreal Cognitive Assessment (MoCA) (31) for poststroke follow-up, both in clinical and research settings.

Other studies (32) have shown a 12-month prevalence of depression of up to 36%. The prevalence of symptoms of anxiety and depression in the current sample was lower, probably due to low presence of known risk factors, such as diabetes, female sex and severe stroke (32). Fatigue is a common hidden impairment after stroke and the one-year prevalence in previous studies has been reported to be 30-60% (27). In the current study, the prevalence of FSS score ≥ 4 points was 33% for the whole sample. Likewise, 25% of all patients reported symptoms of apathy. This is similar to rates reported in other studies (33).

The concept of cognitive domains may be challenging, since domains often interact and overlap. Cognitive tests are most often sensitive to alterations in more than one cognitive domain, e.g. the Clock Drawing test, which assesses both visuospatial ability and executive functioning, or the verbal fluency tests that evaluate language abilities, executive functioning and processing speed (34). Executive functioning is, by definition, thought to involve multiple cognitive domains in a hierarchical manner, where intact executive functions "control" other cognitive abilities. Still, in order to conceptualize cognitive functioning through cognitive assessment in clinical practice, test results, in a diagnostic process, need to be translated into cognitive domains. The 5th edition of the Diagnostic and Statistical Manual

of Mental Disorders (DSM-5) criteria supports the assessment of different cognitive domains, but with no strict recommendation for preferred tests (35). Although the validity of cognitive domains may be questioned, we have chosen to relate cognitive tests to cognitive domains in accordance with clinical practice (34).

During the last decade it has been discussed whether the presence of depression may enhance or even cause cognitive impairment (36). Conversely, cognitive impairment seems to be associated with emotional symptoms (37). The current study found that 28% of patients had a combination of both cognitive and emotional symptoms one year after stroke.

A stroke can change the life of patients in several ways; physically, cognitively and emotionally (9). In clinical practice, an exact diagnosis of specific symptoms may be difficult to establish, since cognitive and emotional symptoms often overlap. A feeling of general "slowness" after stroke may, for instance, be caused by executive dysfunction, fatigue, apathy, or depression, either isolated or in combination. It may be difficult, or in many cases even irrelevant, to distinguish the different cognitive and emotional symptoms from each other, since the patients' most important experience and complaint often is a "feeling of being different" from their premorbid state.

Some of the study patients who completed the 12-month follow-up reported memory, attention and concentration difficulties, which led to bad mood, tiredness, and exhaustion. On the other hand, some patients reported that fatigue also resulted in such difficulties. Almost all patients who completed the 12-month followup were free of obvious focal neurological deficits, and their functional level according to the mRS and Barthel Index was high. Cognitive and emotional deficits were not visible, or, in other words, they were hidden for the patients' surroundings. One in 3 patients had both cognitive and emotional impairments at the same time one year after stroke. Since it is difficult to determine the order of their appearance, we consider that such deficits have to be seen, not only separately, but also as an entity. Like other authors (10), we consider the concept of the "syndrome of hidden impairments" is the best way to define the combination of these invisible stroke sequelae.

Today, very few stroke units and outpatient clinics utilize diagnostic, therapeutic or rehabilitation options for patients with mild or no visible impairments after stroke. It is likely that future stroke units will need to broaden the focus, and acquire competence that is relevant even for patients with mild impairments (38).

Study limitations and strengths

One of the inclusion criteria for this study was that patients should be cognitively healthy pre-stroke. This

information was obtained through asking patients, their dependents, and their family doctors, or by reviewing patients' hospital medical records. Thereby, a possible under-reporting of cognitive symptoms before stroke might bias the results. We therefore chose to screen cognitive function in all the stroke patients 70 years or younger admitted to our 2 stroke units by asking their dependents to complete the 16-item IQCODE. A limitation is that this questionnaire is validated for an elderly population (13).

Strengths of the present study are the consecutive inclusion of patients with a clear diagnosis of a first-ever stroke and the application of an extensive battery of instruments covering relevant cognitive and emotional domains. The choice of such a wide panel of cognitive tests was eligible for diagnosing mild cognitive disorder due to the VASCOG criteria (25). By choosing a cut-off of –1 SD below appropriate norms, and without correction for multiple tests, mild cognitive disorders might have been overdiagnosed in some cases.

Three out of 4 study participants were male. This high proportion of male patients is in accordance with known stroke epidemiology (39). The research team evaluated all the patients aged 18–70 years admitted to the 2 stroke units during the inclusion period. Only 2 patients did not wish to participate. Another strength of the study is the low attrition bias, since only 5 of the included patients declined to complete the follow-up period.

In conclusion, younger patients with stroke, but without obvious neurological symptoms and findings, frequently have hidden impairments, such as subtle cognitive decline, fatigue, and emotional symptoms one year after first-ever stroke. It is important to offer an evaluation of their cognitive and emotional status by using a wide screening battery up to 12 months after stroke. The focus on patients with mild impairments needs to be strengthened in stroke units and stroke outpatient clinics. Further studies should focus on identifying cognitive and emotional instruments to use in the clinical routine follow-up of these patients, and how such identified impairments may affect patients' social and family life.

ACKNOWLEDGEMENTS

The authors thank the patients who participated in the study. In addition, we thank the physicians, nurses, physiotherapists and occupational therapists in the stroke units and the stroke outpatient clinics at Oslo University Hospital and Bærum Hospital for their contribution in selecting, examining, and following up the included patients. Occupational therapists Elisabeth Kjelgaard, Sonja Aune, Karla Ascencio (Oslo University Hospital) and nurse Anne-Mette Brenden (Bærum Hospital) contributed by performing cognitive and emotional assessments. *Sources of funding*. Department of Geriatric Medicine, Oslo University Hospital.

The authors have no conflict of interests to declare.

REFERENCES

- Langhorne P, Ramachandra S. Organised inpatient (stroke unit) care for stroke: Network meta-analysis. The Cochrane database of systematic reviews 2020; (4): Cd000197.
- Lindekleiv H, Berge E, Bruins Slot KM, Wardlaw JM. Percutaneous vascular interventions versus intravenous thrombolytic treatment for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2018; 10: Cd009292.
- Ihle-Hansen H, Thommessen B, Fagerland MW, Wyller TB, Engedal K, Oksengard AR, et al. Impact of white matter lesions on cognition in stroke patients free from pre-stroke cognitive impairment: a one-year follow-up study. Dement Geriatr Cogn Dis Extra 2012; 2: 38–47.
- Fang Y, Mpofu E, Athanasou J. Reducing depressive or anxiety symptoms in post-stroke patients: Pilot trial of a constructive integrative psychosocial intervention. Int J Health Sci (Qassim) 2017; 11: 53–58.
- Makin SD, Turpin S, Dennis MS, Wardlaw JM. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. J Neurol Neurosurg Psychiatry 2013: 84: 893–900.
- Douven E, Kohler S, Schievink SHJ, van Oostenbrugge RJ, Staals J, Verhey FRJ, et al. Temporal associations between fatigue, depression, and apathy after stroke: results of the cognition and affect after stroke, a prospective evaluation of risks study. Cerebrovasc Dis 2017; 44: 330–337.
- Pendlebury ST, Rothwell PM. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study. Lancet Neurol 2019; 18: 248–258.
- Campbell Burton CA, Murray J, Holmes J, Astin F, Greenwood D, Knapp P. Frequency of anxiety after stroke: a systematic review and meta-analysis of observational studies. Int J Stroke 2013; 8: 545–559.
- Parks NE, Eskes GA, Gubitz GJ, Reidy Y, Christian C, Phillips SJ. Fatigue impact scale demonstrates greater fatigue in younger stroke survivors. Can J Neurol Sci 2012; 39: 619–625.
- Jaillard A, Naegele B, Trabucco-Miguel S, LeBas JF, Hommel M. Hidden dysfunctioning in subacute stroke. Stroke 2009; 40: 2473–2479.
- 11. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. Arch Neurol 1989; 46: 660-662.
- Fischer U, Baumgartner A, Arnold M, Nedeltchev K, Gralla J, De Marchis GM, et al. What is a minor stroke? Stroke 2010; 41: 661–666.
- Jorm AF. The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr 2004; 16: 275–293.
- Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ 1980; 58: 113–130.
- Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35–41.
- Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521–1526.
- Sulter G, Steen C, De Keyser J. Use of the Barthel Index and modified Rankin scale in acute stroke trials. Stroke 1999; 30: 1538–1541.
- 18. Strobel C, Engedal K. Norwegian revised Mini Mental Status evaluation. Revised and extended manual. Tønsberg/Oslo: Forlaget Aldring og helse; 2008 (in Norwegian).
- 19. Crum RM, Anthony JC, Bassett SS, Folstein MF. Populationbased norms for the Mini-Mental State Examination by

- age and educational level. JAMA 1993; 269: 2386–2391. 20. Shulman KI, Pushkar Gold D, Cohen CA, Zucchero CA. Clock-drawing and dementia in the community: a longi-
- tudinal study. Int J Geriatr Psychiatry 1993; 8: 487–496.
 21. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol
- 2004; 19: 203–214.
 22. Egeland J, Landro NI, Tjemsland E, Walbaekken K. Norwegian norms and factor-structure of phonemic and semantic word list generation. Clin Neuropsychol 2006; 20: 716–728.
- Fastenau PS, Denburg NL, Hufford BJ. Adult norms for the Rey-Osterrieth Complex Figure Test and for supplemental recognition and matching trials from the Extended Complex Figure Test. Clin Neuropsychol 1999; 13: 30–47.
- Delis DC, Kramer JH, Kaplan E, Thompkins BAO, Corporation P, Harcourt Brace Jovanovich I. CVLT: California Verbal Learning Test-Adult Version: Manual: Psychological Corporation; 1987.
- Sachdev P, Kalaria R, O'Brien J, Skoog I, Alladi S, Black SE, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord 2014; 28: 206–218.
- 26. Aben I, Verhey F, Lousberg R, Lodder J, Honig A. Validity of the beck depression inventory, hospital anxiety and depression scale, SCL-90, and Hamilton Depression Rating Scale as screening instruments for depression in stroke patients. Psychosomatics 2002; 43:386–393.
- 27. Cumming TB, Packer M, Kramer SF, English C. The prevalence of fatigue after stroke: A systematic review and meta-analysis. Int J Stroke 2016; 11: 968–977.
- Andersson S, Krogstad JM, Finset A. Apathy and depressed mood in acquired brain damage: relationship to lesion localization and psychophysiological reactivity. Psychol Med 1999; 29: 447–456.
- 29. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993; 150: 286–293.
- 30. Nys GM, van Zandvoort MJ, de Kort PL, Jansen BP, Kappelle LJ, de Haan EH. Restrictions of the Mini-Mental State Examination in acute stroke. Arch Clin Neuropsychol 2005; 20: 623–629.
- 31. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–699.
- 32. Robinson RG, Jorge RE. Post-stroke depression: a review. Am J Psychiatry 2016; 173: 221–231.
- van Dalen JW, Moll van Charante EP, Nederkoorn PJ, van Gool WA, Richard E. Poststroke apathy. Stroke 2013; 44: 851–860.
- 34. Harvey PD. Domains of cognition and their assessment. Dialogues Clin Neurosci 2019; 21: 227–237.
- Association AP. Diagnostic and Statistical Manual of Mental Disorders DSM-5. 5th ed. Arlington, VA: American Psyciatric Association; 2013.
- Srisurapanont M, Bautista D, Chen CH, Wang G, Udomratn P, Eurviriyanukul K. Subjective memory and concentration deficits in medication-free, non-elderly Asians with major depressive disorder: prevalence and their correlates. J Affect Disord 2015; 171: 105–110.
- 37. Knight MJ, Lyrtzis E, Baune BT. The association of cognitive deficits with mental and physical quality of life in major depressive disorder. Compr Psychiatry 2020; 97: 152147.
- Thomassen L, Waje-Andreassen U, Broegger J, Naess H. Acute stroke centre - the changing focus of stroke unit care. The Bergen NORSTROKE Study. Acta Neurol Scand 2012; 125: 410–415.
- 39. Thrift AG, Thayabaranathan T, Howard G, Howard VJ, Rothwell PM, Feigin VL, et al. Global stroke statistics. Int J Stroke 2017; 12: 13–32.